BMY Bristol-Myers Squibb Co.
19,097
$44.04
$0.14
(0.32%)
| Watchers | 19,097 |
| 52-Wk Low | $43.33 |
| 52-Wk High | $69.10 |
| Market Cap | $88.99B |
| Volume | 1.77M |
| 52-Wk High | $69.10 |
| 52-Wk Low | $43.33 |
Bristol Myers Squibb to Participate in Upcoming Investor ConferencesBusiness Wire • about 4 hours ago
Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in two upcoming investor conferences in May 2024. Ben Hickey, President, RayzeBio, Head of Mirati, will take part in...
Share to Feed
European Medicines Agency Validates Bristol Myers Squibbs Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite...
Scenic Biotech, a pioneer in the field of modifier therapies for severe genetic disorders, today announced that it has entered into a research collaboration with Bristol Myers Squibb (NYSE: BMY) to...
Repertoire Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases Repertoire Immune Medicines and Bristol Myers...
Latest Ratings for BMY
DateFirmActionFromTo Mar 2022Wells FargoMaintainsEqual-Weight Dec 2021Goldman SachsInitiates Coverage OnBuy Dec 2021Wells FargoInitiates Coverage OnEqual-Weight
View...
Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo (nivolumab...
Bristol-Myers Squibb Company (NYSE: BMY) reported an adjusted loss per share of $4.40, narrower than the Zacks Consensus Estimate of a loss of $4.53 per share. In the year-ago quarter, BMY posted...
Pharma giants Merck and Bristol-Myers Squibb are both getting ready for some of their key drug patents to expire in the next few years. Both companies reported quarterly earning Thursday, providing...